97 related articles for article (PubMed ID: 9707043)
1. Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients.
Lam KY; Lo CY
Am J Gastroenterol; 1998 Aug; 93(8):1232-5. PubMed ID: 9707043
[TBL] [Abstract][Full Text] [Related]
2. Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients.
Dong M; Nio Y; Tamura K; Song MM; Guo KJ; Guo RX; Dong YT
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):279-84. PubMed ID: 10750666
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity in pancreatic endocrine tumors.
Tang SJ; Dumot JA; Wang L; Memmesheimer C; Conwell DL; Zuccaro G; Goormastic M; Ormsby AH; Cowell J
Am J Gastroenterol; 2002 Apr; 97(4):1022-30. PubMed ID: 12003383
[TBL] [Abstract][Full Text] [Related]
4. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
[TBL] [Abstract][Full Text] [Related]
5. Deletion of chromosome 1, but not mutation of MEN-1, predicts prognosis in sporadic pancreatic endocrine tumors.
Guo SS; Wu AY; Sawicki MP
World J Surg; 2002 Jul; 26(7):843-7. PubMed ID: 11960210
[TBL] [Abstract][Full Text] [Related]
6. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival.
Sessa F; Bonato M; Bisoni D; Ranzani GN; Capella C
Eur J Histochem; 1998; 42 Spec No():67-76. PubMed ID: 10076772
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
8. Cell adhesion molecule 1 is a novel pancreatic-islet cell adhesion molecule that mediates nerve-islet cell interactions.
Koma Y; Furuno T; Hagiyama M; Hamaguchi K; Nakanishi M; Masuda M; Hirota S; Yokozaki H; Ito A
Gastroenterology; 2008 May; 134(5):1544-54. PubMed ID: 18471525
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the Sm-like proto-oncogene in primary and metastatic pancreatic endocrine tumors.
Gumbs AA; Bassi C; Moore PS; Falconi M; Frigerio I; Baron A; Piemonti L; Modlin I; Scarpa A
JOP; 2002 Jul; 3(4):109-15. PubMed ID: 12110768
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors.
Srivastava A; Alexander J; Lomakin I; Dayal Y
Hum Pathol; 2001 Nov; 32(11):1184-9. PubMed ID: 11727256
[TBL] [Abstract][Full Text] [Related]
12. DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors.
Perren A; Saremaslani P; Schmid S; Bonvin C; Locher T; Roth J; Heitz PU; Komminoth P
Diagn Mol Pathol; 2003 Dec; 12(4):181-6. PubMed ID: 14639103
[TBL] [Abstract][Full Text] [Related]
13. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
14. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
15. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
16. [The relationship between tumor suppressor genes p14ARF and p53 expression and biological behavior of pancreatic carcinoma].
Chen XL; Zhang QH; Ni QX
Zhonghua Yi Xue Za Zhi; 2003 May; 83(10):868-71. PubMed ID: 12895341
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets.
Capurso G; Lattimore S; Crnogorac-Jurcevic T; Panzuto F; Milione M; Bhakta V; Campanini N; Swift SM; Bordi C; Delle Fave G; Lemoine NR
Endocr Relat Cancer; 2006 Jun; 13(2):541-58. PubMed ID: 16728581
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PCNA, p53, K-ras and LOH in endocrine pancreas tumors.
Sato T; Konishi K; Kimura H; Maeda K; Yabushita K; Tsuji M; Miwa A
Hepatogastroenterology; 2000; 47(33):875-9. PubMed ID: 10919051
[TBL] [Abstract][Full Text] [Related]
19. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications.
Rigaud G; Missiaglia E; Moore PS; Zamboni G; Falconi M; Talamini G; Pesci A; Baron A; Lissandrini D; Rindi G; Grigolato P; Pederzoli P; Scarpa A
Cancer Res; 2001 Jan; 61(1):285-92. PubMed ID: 11196176
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.
Beghelli S; Pelosi G; Zamboni G; Falconi M; Iacono C; Bordi C; Scarpa A
J Pathol; 1998 Sep; 186(1):41-50. PubMed ID: 9875139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
